Jefferies raised the firm’s price target on Terns Pharmaceuticals (TERN) to $35 from $28 and keeps a Buy rating on the shares after the company reported 6-month data for TERN-701’s Phase 1 CARDINAL trial in Chronic Myeloid Leukemia in the ASH abstracts. The firm thinks this early dataset looks best-in-class and justifies moving forward in both a first-line and second-line or later setting in Chronic Myeloid Leukemia.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
- Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue
- William Blair upgrades Terns Pharmaceuticals after ‘impressive’ data
- Terns Pharmaceuticals upgraded to Outperform from Market Perform at William Blair
- Terns Pharmaceuticals Announces CARDINAL Trial Data Presentation